Neuroscience

Advancing patient care in neurodegenerative diseases with unmet medical needs

AstraZeneca is committed to discovering and developing compounds to improve patient care in neuroscience.

With a rich heritage and a research and development focus on specific aspects of neurodegenerative diseases, analgesia and psychiatry, AstraZeneca continues to push the boundaries of science in neuroscience in collaboration with other innovative partners across industry and academia. A significant unmet medical need remains in the areas of cognitive disorders, chronic pain and other central nervous system disorders. 

 

Collaboration stories

Partnering with influential organisations to extend the reach of our science to more patients and healthcare providers

Our focus on unmet medical needs

More than 450 million people worldwide are affected by mental, neurological or behavioural problems, and the number is steadily rising.

  • Opioid-induced constipation (OIC)

    OIC is a condition caused by prescription opioid pain medicines. Millions of patients are treated with opioids each year.


  • Alzheimer's disease (AD)

    AD is a fatal illness that causes progressive decline in memory and other aspects of cognition.


Opportunities for collaboration

Our approach in Neuroscience looks to maximise revenue through externalisation and on-market products; advance the novel product pipeline with partnerships where appropriate; and preserve a company stake in the most promising assets.


Kate's story


What we're working on

We are committed to developing novel therapies that advance the science of neurodegenerative diseases and have the potential to provide a positive impact on patients around the world.

        Image: Artistic rendering of BACE enzyme.

Our pipeline

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.

Phase 3/Reg.* refers to assets that are in Phase 3 or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets.

Neuroscience (as at 27 July 2017)

Phase 1

Phase 1

Phase 2

Phase 2

Phase 3

Phase 3

  • lanabecestat AMARANTH + extension, DAYBREAK-ALZ Alzheimer's disease

LCM Projects

LCM Projects




Our medicines

Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.

  • Diprivan propofol
  • EMLA EMLA
  • Movantik/Moventig naloxegol
  • Naropin ropivacaine
  • Seroquel IR quetiapine fumarate
  • Seroquel XR quetiapine fumarate
  • Xylocaine lidocaine
  • Zomig, Zomig Rapimelt, Zomig Nasal Spray, AscoTop, Zomigon zolmitriptan

Resources




Veeva ID: Z4-3582
Date of next review: March 2018